Fortress Biotech (FBIO) News Today $1.81 -0.05 (-2.69%) As of 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Fortress Biotech (NASDAQ: FBIO) Receives Notification of Extended FDA Target Action Date for CUTX-101January 19 at 2:07 AM | americanbankingnews.comShort Interest in Fortress Biotech, Inc. (NASDAQ:FBIO) Expands By 9.3%Fortress Biotech, Inc. (NASDAQ:FBIO - Get Free Report) was the recipient of a significant growth in short interest in the month of December. As of December 31st, there was short interest totalling 3,400,000 shares, a growth of 9.3% from the December 15th total of 3,110,000 shares. Currently, 17.2% of the shares of the company are sold short. Based on an average daily volume of 653,000 shares, the days-to-cover ratio is currently 5.2 days.January 18, 2025 | marketbeat.comFDA extends review of Fortress Biotech's CUTX-101 drugJanuary 16, 2025 | msn.comFortress, Cyprium announce FDA acceptance, priority review of NDA for CUTX-101January 7, 2025 | markets.businessinsider.comFortress Biotech and Cyprium Therapeutics Announce U.S. FDA Acceptance and Priority Review of NDA for CUTX-101 for Treatment of Menkes DiseaseJanuary 6, 2025 | globenewswire.comSentynl Therapeutics Announces U.S. FDA Acceptance and Priority Review of New Drug Application for CUTX-101 (Copper Histidinate) Product Candidate for Treatment of Menkes DiseaseJanuary 6, 2025 | prnewswire.comFortress Biotech (NASDAQ:FBIO) Stock Price Passes Above 200-Day Moving Average - What's Next?Fortress Biotech (NASDAQ:FBIO) Shares Pass Above Two Hundred Day Moving Average - Should You Sell?January 1, 2025 | marketbeat.comFortress Biotech, Inc. Common Stock (FBIO) Analyst ResearchDecember 23, 2024 | nasdaq.comCheckpoint Therapeutics Announces FDA Approval of UNLOXCYT™ (cosibelimab-ipdl)December 13, 2024 | globenewswire.comFortress Biotech price target raised to $15 from $13 at Roth MKMNovember 20, 2024 | markets.businessinsider.comFortress Biotech price target raised to $26 from $24 at H.C. WainwrightNovember 18, 2024 | markets.businessinsider.comFortress Biotech price target lowered to $4 from $5 at Alliance Global PartnersNovember 18, 2024 | markets.businessinsider.comFortress Biotech’s Q3 2024 Earnings and FDA MilestoneNovember 15, 2024 | markets.businessinsider.comFortress Biotech Reports Third Quarter 2024 Financial Results and Recent Corporate HighlightsNovember 14, 2024 | globenewswire.comCheckpoint Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate UpdatesNovember 12, 2024 | globenewswire.comJourney Medical Corporation Reports Third Quarter 2024 Financial Results and Recent Corporate HighlightsNovember 12, 2024 | globenewswire.comJourney Medical Corporation Announces U.S. FDA Approval of Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of RosaceaNovember 4, 2024 | globenewswire.comHighbridge Capital Management's Strategic Acquisition of Fortress Biotech SharesOctober 25, 2024 | uk.finance.yahoo.comJourney Medical Corporation Announces DFD-29 Data Presented at 44th Fall Clinical Dermatology ConferenceOctober 25, 2024 | globenewswire.comJourney Medical Corporation to Participate in the 3rd Annual ROTH Healthcare Opportunities ConferenceOctober 3, 2024 | globenewswire.comFortress Biotech to Participate in October 2024 Investor ConferencesSeptember 26, 2024 | globenewswire.comLindsay A. Md Rosenwald Buys 763,359 Shares of Fortress Biotech, Inc. (NASDAQ:FBIO) StockSeptember 26, 2024 | insidertrades.comFortress Biotech secures $8 million in stock salesSeptember 22, 2024 | investing.comWhy Fortress Biotech (FBIO) Stock Is Getting HammeredSeptember 20, 2024 | msn.comFortress Biotech Announces Pricing of $8 Million Registered Direct Offering and Concurrent Private PlacementsSeptember 20, 2024 | globenewswire.comCheckpoint Therapeutics Announces Cosibelimab Longer-Term Results in Advanced Cutaneous Squamous Cell Carcinoma Presented at ESMO Congress 2024September 16, 2024 | globenewswire.comJourney Medical Corporation to Participate in the Lake Street Capital Markets 8th Annual Best Ideas Growth (BIG) ConferenceSeptember 9, 2024 | globenewswire.comFortress Biotech to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 4, 2024 | globenewswire.comJourney Medical Corporation to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 4, 2024 | globenewswire.comCheckpoint Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 4, 2024 | globenewswire.comFBIO Sep 2024 5.000 call (FBIO240920C00005000)August 18, 2024 | finance.yahoo.comFortress Biotech Reports Second Quarter 2024 Financial Results and Recent Corporate HighlightsAugust 13, 2024 | globenewswire.comJourney Medical Corporation Reports Second Quarter 2024 Financial Results and Recent Corporate HighlightsAugust 12, 2024 | globenewswire.comCheckpoint Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate UpdatesAugust 12, 2024 | globenewswire.comJourney Medical Corporation to Announce Second Quarter 2024 Financial Results on August 12, 2024August 6, 2024 | globenewswire.comFortress Biotech Reduces Total Debt and Enters into New $35 Million Term Loan with Oaktree with Maturity in 2027July 25, 2024 | globenewswire.comCheckpoint Therapeutics Announces FDA Acceptance of BLA Resubmission of Cosibelimab for the Treatment of Advanced Cutaneous Squamous Cell CarcinomaJuly 25, 2024 | globenewswire.comFortress Biotech’s Strategic Financial Moves and Clinical Pipeline Promise Bright Revenue Prospects: Pantginis Issues Buy RatingJuly 19, 2024 | markets.businessinsider.comLindsay A. Md Rosenwald Acquires 5,000 Shares of Fortress Biotech, Inc. (NASDAQ:FBIO) StockJuly 16, 2024 | insidertrades.comGC Cell and Checkpoint Therapeutics Advance Collaborative Cancer ResearchJuly 15, 2024 | globenewswire.comJourney Medical Corporation Appoints Michael C. Pearce to Board of DirectorsJuly 11, 2024 | globenewswire.comFortress Biotech Announces Pause in Payment of Dividends on 9.375% Series A Cumulative Redeemable Perpetual Preferred StockJuly 5, 2024 | globenewswire.comCheckpoint Therapeutics Announces $12 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesJuly 2, 2024 | globenewswire.comCheckpoint Therapeutics Announces Biologics License Application Resubmission for CosibelimabJuly 2, 2024 | globenewswire.comLindsay A. Md Rosenwald Buys 20,000 Shares of Fortress Biotech, Inc. (NASDAQ:FBIO) StockJuly 2, 2024 | insidertrades.comCheckpoint Therapeutics Announces Alignment with FDA Enabling Upcoming Cosibelimab BLA ResubmissionJune 24, 2024 | globenewswire.comInsider Buying: Fortress Biotech, Inc. (NASDAQ:FBIO) CEO Buys 10,000 Shares of StockMay 21, 2024 | insidertrades.comAnalysts Are Bullish on Top Healthcare Stocks: Fortress Biotech (FBIO), BioLife Solutions (BLFS)May 16, 2024 | markets.businessinsider.comFortress Biotech, Inc.: Fortress Biotech Reports First Quarter 2024 Financial Results and Recent Corporate HighlightsMay 16, 2024 | finanznachrichten.deFortress Biotech to Participate in the Alliance Global Partners’ (A.G.P.) Virtual Healthcare Company ShowcaseMay 16, 2024 | finance.yahoo.com Get Fortress Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for FBIO and its competitors with MarketBeat's FREE daily newsletter. Email Address FBIO Media Mentions By Week FBIO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. FBIO News Sentiment▼0.740.64▲Average Medical News Sentiment FBIO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. FBIO Articles This Week▼31▲FBIO Articles Average Week Get Fortress Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for FBIO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies LXRX News ACHV News AGEN News RGLS News SABS News CRIS News BOLT News MTEM News AMGN News GILD News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:FBIO) was last updated on 1/22/2025 by MarketBeat.com Staff From Our PartnersMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is ...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredNow that Trump’s be inaugurated, this day will be key (mark your calendar)Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredTexas embraces new currencyRural Texas Town Ramps Up Global Currency War A small town has joined a radical $1.9 trillion attack on the...Stansberry Research | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fortress Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Fortress Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
